%0 Journal Article
%A Faehling, Martin
%A Fallscheer, Sabine
%A Schmiederer, Julia
%A Sträter, Jörn
%A Christopoulos, Petros
%A Lengerke, Claudia
%A Seifarth, Harald
%T Pattern of brain metastases and survival in lung adenocarcinoma with KRAS or EFGR mutation.
%J Lung cancer
%V 209
%@ 0169-5002
%C Amsterdam [u.a.]
%I Elsevier
%M DKFZ-2025-02224
%P 108803
%D 2025
%X NSCLC with mutations of the KRAS or EGFR gene is associated with a high risk of brain metastases (BRA). There are few data on the prevalence and pattern of BRA and on survival in unselected KRAS or EGFR patients.This real-world analysis (KOMPASS-study) included 326 NSCLC patients with stage IV adenocarcinoma and either KRAS mutation (n = 90), EGFR mutation (n = 87), or no known driver mutation (n = 149). Prevalence, number, and size of BRA, and the effect of BRA on overall survival (OS) were analyzed.The prevalence of BRA was higher in KRAS patients (40 
%K CNS metastases (Other)
%K EGFR (Other)
%K Exon 21 (Other)
%K G12C (Other)
%K KRAS (Other)
%K Lung cancer (Other)
%K Number of brain metastases (Other)
%K Overall survival (Other)
%K Real world data (Other)
%K Size (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:41151358
%R 10.1016/j.lungcan.2025.108803
%U https://inrepo02.dkfz.de/record/305554